Jeligo

Linagliptin, the active ingredient in Jeligo, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jeligo is a DPP‑4 inhibitor used to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves blood glucose levels as monotherapy or in combination with other antidiabetic agents. - Adjunct to diet and exercise: helps achieve target HbA1c when used with lifestyle measures. - Combination therapy with insulin: provides additional glucose‑lowering effect in patients requiring insulin.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Dizziness: occasional sensation of light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Back pain: occasional musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

Before initiating therapy, consider the following precautions: - Renal impairment: assess kidney function and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if rash, swelling or breathing difficulty occurs. - Pregnancy: avoid unless the potential benefit outweighs the risk; safety not established. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia. Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - Warfarin: observe INR values for potential alteration. - ACE inhibitors: watch for changes in blood pressure or renal function.